Jamie Stiff
Managing Director @ Genesys Capital
Toronto, Canada
Jamie Stiff is a Series B investor at Genesys Capital in Toronto focused on Biotechnology and Medical. Jamie Stiff - Managing Director @ Genesys Capital
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jamie Stiff invests in
Stages Jamie Stiff invests in
Countries Jamie Stiff invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (50%)
- Medical 3 (38%)
- Health Care 3 (38%)
- Therapeutics 3 (38%)
- Biopharma 2 (25%)
Stage
- Series B 3 (38%)
- Series A 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
- Funding Round 1 (13%)
Country
- Canada 3 (38%)
- United States 2 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Enspire DBS Therapy supports stroke recovery patients using deep brain stimulation with physical rehabilitation to restore motor function. Enspire DBS offers a robust method to mediate the effects of stimulation and stroke rehabilitation. | $10.3M / Series B / Jan 13, 2026 | ||
| Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $21M / Series B / Sep 04, 2024 | ||
| Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $24M / Jun 20, 2023 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | ||
| Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $16.6M / Series A / Jun 16, 2021 | ||
| Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M / Seed / May 21, 2021 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M / Series B / Sep 08, 2020 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M / Series A / Jul 25, 2018 |
Co-Investors
About Genesys Capital
Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising biotechnology investment opportunities.
Genesys Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Damian Lamb
Co-Founder and Managing Director
|
|||
|
Jamie Stiff
Managing Director
|
|||
Jennifer Williams
Partner and CFO; Director of Finance and Operations
|
|||
Kelly Holman
Co-Founder and Managing Director
|
|||
Maxime Ranger
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jamie Stiff invest in?
Jamie Stiff invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jamie Stiff?
Public channels for Jamie Stiff include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jamie Stiff last invest?
The most recent investment recorded for Jamie Stiff closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
